Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix
Objective This study elucidated the efficacy of Relugolix (REL) on the reduction of uterine volume and clinical symptoms for the treatment of adenomyosis.Methods We conducted a retrospective cohort study of patients who received REL (40 mg for about 20 weeks) and who underwent a hysterectomy for ade...
Saved in:
Main Authors: | Keitaro Yamanaka (Author), Keiichi Washio (Author), Akiko Uchida (Author), Yuki Sasagawa (Author), Masashi Nishimoto (Author), Yui Yamasaki (Author), Satoshi Nagamata (Author), Yoshito Terai (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy
by: Yukifumi Sasamori, et al.
Published: (2021) -
A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma
by: Maho Shimizu, et al.
Published: (2021) -
A Case of Significant Response to Olaparib in a Patient with Primary Peritoneal Carcinosarcoma Diagnosed by Laparoscopic Surgery
by: Satoshi Nagamata, et al.
Published: (2020) -
Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study
by: Yoshimitsu Wada, et al.
Published: (2023) -
Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial
by: Hiroshi Hoshiai, et al.
Published: (2021)